164 related articles for article (PubMed ID: 11762817)
21. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
22. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
24. Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Reiser M; Josting A; Dias Wickramanayake P; Draube A; Scheid C; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 1999 Apr; 33(3-4):305-12. PubMed ID: 10221510
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
[TBL] [Abstract][Full Text] [Related]
26. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU).
Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A
Am J Hematol; 2017 Oct; 92(10):1004-1010. PubMed ID: 28614905
[TBL] [Abstract][Full Text] [Related]
30. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
31. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
Lignon J; Sibon D; Madelaine I; Brice P; Franchi P; Briere J; Mounier N; Gisselbrecht C; Faure P; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):262-9. PubMed ID: 20709662
[TBL] [Abstract][Full Text] [Related]
32. ASHAP--an effective salvage therapy for recurrent and refractory malignant lymphomas.
Hänel M; Kröger N; Hoffknecht MM; Peters SO; Metzner B; Fiedler F; Braumann D; Schubert JC; Illiger HJ; Hänel A; Krüger WH; Zeller W; Weh HJ; Hossfeld DK; Zander AR
Ann Hematol; 2000 Jun; 79(6):304-11. PubMed ID: 10901609
[TBL] [Abstract][Full Text] [Related]
33. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Sym SJ; Lee DH; Kang HJ; Nam SH; Kim HY; Kim SJ; Eom HS; Kim WS; Suh C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):27-33. PubMed ID: 18839172
[TBL] [Abstract][Full Text] [Related]
34. Comparative toxicities of 3 platinum-containing chemotherapy regimens in relapsed/refractory lymphoma patients.
Tixier F; Ranchon F; Iltis A; Vantard N; Schwiertz V; Bachy E; Bouafia-Sauvy F; Sarkozy C; Tournamille JF; Gyan E; Salles G; Rioufol C
Hematol Oncol; 2017 Dec; 35(4):584-590. PubMed ID: 27377614
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma.
Lazzarino M; Orlandi E; Montillo M; Tedeschi A; Pagnucco G; Astori C; Corso A; Brusamolino E; Simoncini L; Morra E; Bernasconi C
Ann Oncol; 1999 Jan; 10(1):59-64. PubMed ID: 10076723
[TBL] [Abstract][Full Text] [Related]
36. FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Child JA; Johnson SA; Rule S; Smith GM; Morgan GJ; Johnson PW; Prentice AG; Tollerfield SM; Wareham E
Leuk Lymphoma; 2000 Apr; 37(3-4):309-17. PubMed ID: 10752982
[TBL] [Abstract][Full Text] [Related]
37. [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma].
Yamamura R; Yamane T; Aoyama Y; Nakamae H; Hasegawa T; Ohta K; Nakao Y; Ohta T; Mugitani A; Hino M
Gan To Kagaku Ryoho; 2004 Mar; 31(3):373-5. PubMed ID: 15045943
[TBL] [Abstract][Full Text] [Related]
38. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
39. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Haim N; Ben-Shahar M; Faraggi D; Tsuri-Etzioni A; Leviov M; Epelbaum R
Cancer; 1997 Nov; 80(10):1989-96. PubMed ID: 9366303
[TBL] [Abstract][Full Text] [Related]
40. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Girouard C; Dufresne J; Imrie K; Stewart AK; Brandwein J; Prince HM; Pantolony D; Keating A; Crump M
Ann Oncol; 1997 Jul; 8(7):675-80. PubMed ID: 9296221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]